Pharmacokinetics of Lopinavir and Ritonavir in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19).
作者信息
Schoergenhofer Christian, Jilma Bernd, Stimpfl Thomas, Karolyi Mario, Zoufaly Alexander
机构信息
Medical University of Vienna, Vienna, Austria (C.S., B.J., T.S.).
Kaiser-Franz-Josef-Hospital, Vienna, Austria (M.K., A.Z.).
出版信息
Ann Intern Med. 2020 Oct 20;173(8):670-672. doi: 10.7326/M20-1550. Epub 2020 May 12.
Abstract
摘要
相似文献
1
Pharmacokinetics of Lopinavir and Ritonavir in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19).洛匹那韦和利托那韦在2019冠状病毒病（COVID-19）住院患者中的药代动力学
Ann Intern Med. 2020 Oct 20;173(8):670-672. doi: 10.7326/M20-1550. Epub 2020 May 12.
2
Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect.在新冠肺炎患者中停用洛匹那韦/利托那韦：药物相互作用效应的持续时间。
J Antimicrob Chemother. 2020 Oct 1;75(10):3084-3086. doi: 10.1093/jac/dkaa253.
3
Lopinavir pharmacokinetics in COVID-19 patients.洛匹那韦在新冠肺炎患者中的药代动力学。
J Antimicrob Chemother. 2020 Sep 1;75(9):2702-2704. doi: 10.1093/jac/dkaa195.
4
Lopinavir-Ritonavir Treatment for COVID-19 Infection in Intensive Care Unit: Risk of Bradycardia.洛匹那韦-利托那韦用于重症监护病房中新型冠状病毒肺炎感染的治疗：心动过缓风险
Circ Arrhythm Electrophysiol. 2020 Aug;13(8):e008798. doi: 10.1161/CIRCEP.120.008798. Epub 2020 Jul 9.
5
[Adverse effects of lopinavir/ritonavir in critically ill patients with COVID-19].洛匹那韦/利托那韦对新冠肺炎危重症患者的不良反应
Medicina (B Aires). 2020;80(5):439-441.
6
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.洛匹那韦-利托那韦治疗成人重症 COVID-19 患者的临床试验。
N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282. Epub 2020 Mar 18.
7
Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.SARS-CoV-2 全身炎症反应对洛匹那韦和羟氯喹血浆浓度的影响。
Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.01177-20.
8
Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.抗病毒联合治疗在新冠病毒感染有症状患者中的安全性和有效性 - 一项随机对照试验（SEV-COVID 试验）：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 20;21(1):866. doi: 10.1186/s13063-020-04774-5.
9
[Drug interaction monitoring of lopinavir/ritonavir in COVID-19 patients with cancer].[新冠肺炎合并癌症患者中洛匹那韦/利托那韦的药物相互作用监测]
Zhonghua Nei Ke Za Zhi. 2020 May 1;59(5):400-404. doi: 10.3760/cma.j.cn112138-20200219-00097.
10
BET 1: Lopinavir-ritonavir and COVID-19.赌注1：洛匹那韦-利托那韦与2019冠状病毒病
Emerg Med J. 2020 Jul;37(7):450-451. doi: 10.1136/emermed-2020-210221.2.
引用本文的文献
1
2
COVID-19 drug discovery and treatment options.COVID-19 药物研发和治疗选择。
Nat Rev Microbiol. 2024 Jul;22(7):391-407. doi: 10.1038/s41579-024-01036-y. Epub 2024 Apr 15.
3
SARS-CoV-2 immunity and vaccine strategies in people with HIV.HIV感染者中的新型冠状病毒2型免疫及疫苗策略
Oxf Open Immunol. 2022 Aug 17;3(1):iqac005. doi: 10.1093/oxfimm/iqac005. eCollection 2022.
4
The Role of CYP3A in Health and Disease.细胞色素P450 3A在健康与疾病中的作用
Biomedicines. 2022 Oct 24;10(11):2686. doi: 10.3390/biomedicines10112686.
5
COVID-19 Vaccines and the Virus: Impact on Drug Metabolism and Pharmacokinetics.新型冠状病毒肺炎疫苗与病毒：对药物代谢动力学和药物代谢的影响。
Drug Metab Dispos. 2023 Jan;51(1):130-141. doi: 10.1124/dmd.122.000934. Epub 2022 Oct 23.
6
The Cytokine Release Syndrome and/or the Proinflammatory Cytokines as Underlying Mechanisms of Downregulation of Drug Metabolism and Drug Transport: A Systematic Review of the Clinical Pharmacokinetics of Victim Drugs of this Drug-Disease Interaction Under Different Clinical Conditions.细胞因子释放综合征和/或前炎症细胞因子作为下调药物代谢和药物转运的潜在机制：不同临床条件下该药物-疾病相互作用的致害药物临床药代动力学的系统评价。
Clin Pharmacokinet. 2022 Nov;61(11):1519-1544. doi: 10.1007/s40262-022-01173-8. Epub 2022 Sep 5.
7
Identifying Drug-Induced Liver Injury Associated With Inflammation-Drug and Drug-Drug Interactions in Pharmacologic Treatments for COVID-19 by Bioinformatics and System Biology Analyses: The Role of Pregnane X Receptor.通过生物信息学和系统生物学分析识别新冠病毒病药物治疗中与炎症药物及药物相互作用相关的药物性肝损伤：孕烷X受体的作用
Front Pharmacol. 2022 Aug 1;13:804189. doi: 10.3389/fphar.2022.804189. eCollection 2022.
8
Camostat Mesylate Versus Lopinavir/Ritonavir in Hospitalized Patients With COVID-19-Results From a Randomized, Controlled, Open Label, Platform Trial (ACOVACT).甲磺酸卡莫司他与洛匹那韦/利托那韦用于住院COVID-19患者的疗效比较——一项随机、对照、开放标签、平台试验（ACOVACT）的结果
Front Pharmacol. 2022 Jul 22;13:870493. doi: 10.3389/fphar.2022.870493. eCollection 2022.
9
Atazanavir versus lopinavir on Covid-19 infection: A retrospective protease inhibitors comparative study 2020.阿扎那韦与洛匹那韦治疗新型冠状病毒肺炎感染的疗效比较：一项2020年的回顾性蛋白酶抑制剂对比研究
Caspian J Intern Med. 2022;13(Suppl 3):173-179. doi: 10.22088/cjim.13.0.173.
10
Impact of Inflammation on Midazolam Metabolism in Severe COVID-19 Patients.炎症对重症 COVID-19 患者咪达唑仑代谢的影响。
Clin Pharmacol Ther. 2022 Nov;112(5):1033-1039. doi: 10.1002/cpt.2698. Epub 2022 Jul 27.
本文引用的文献
1
Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19.白细胞介素-6、C 反应蛋白和降钙素原对 COVID-19 患者的预后价值。
J Clin Virol. 2020 Jun;127:104370. doi: 10.1016/j.jcv.2020.104370. Epub 2020 Apr 14.
2
Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro.瑞德西韦、洛匹那韦、依米丁和高三尖杉酯碱在体外抑制 SARS-CoV-2 复制。
Antiviral Res. 2020 Jun;178:104786. doi: 10.1016/j.antiviral.2020.104786. Epub 2020 Apr 3.
3
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.洛匹那韦-利托那韦治疗成人重症 COVID-19 患者的临床试验。
N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282. Epub 2020 Mar 18.
4
Clopidogrel in Critically Ill Patients.氯吡格雷在危重症患者中的应用。
Clin Pharmacol Ther. 2018 Feb;103(2):217-223. doi: 10.1002/cpt.878. Epub 2017 Nov 3.
5
Lopinavir/Ritonavir: a review of its use in the management of HIV-1 infection.洛匹那韦利托那韦：在治疗人类免疫缺陷病毒 1 型感染中的应用评价。
Drugs. 2010 Oct 1;70(14):1885-915. doi: 10.2165/11204950-000000000-00000.
Zotero 插件